Instructions for Authors 2020

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. Each article should include a concrete conclusion constituting of a “new piece of knowledge” backed up by scientific evidence. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal’s secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts exceeding 4 printed pages will be subject to excess page charges. The 4 printed pages correspond approximately to twelve (12) document pages (~250 words per double-spaced typed page in Arial 12), including abstract, text, tables, figures, and references. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Conflicts of Interest; (h) Authors’ contributions; (i) Acknowledgements; (j) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges.

Tables. All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.


**Nomenclature and Abbreviations.** Nomenclature should follow that given in “Chemical Abstracts”, “Index Medicus”, “Merck Index”, “IUPAC -IUB”, “Berger’s Manual of Determinative Bacteriology”, The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (http://www.gene.ucl.ac.uk/). Approved mouse nomenclature may be obtained from http://www.informatics.jax.org/. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

**Clinical Trials.** Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

**Ethical Policies and Standards.** ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

**Submission of Manuscripts.** Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: http://www.iiar-submissions.com/login.html

In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iiar-anticancer.org

**Galley Proofs.** Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004 (upon request to the Subscriptions Office). Galley proofs should be returned corrected to the Editorial Office by email (iiar@iiar-anticancer.org) within two days.

**Specific information and additional instructions for Authors**

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.

2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.

3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.

4. Each manuscript submitted to AR is sent for peer-review in confidence to two-three suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.
5. All accepted manuscripts are carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author’s writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.

6. Authors should pay attention to the following points when writing an article for AR:
   - The Instructions to Authors must be followed in every detail.
   - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
   - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
   - Results given in figures should not be repeated in tables.
   - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
   - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
   - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
   - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
   - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by… authors, year).
   - References. Each article should address, list and discuss the entire spectrum of current publications relevant to its field.
   - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.

7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.

8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).

9. Articles submitted to AR may be rejected without review if:
   - they do not fall within the journal's policy.
   - they do not follow the instructions for authors.
   - language is unclear.
   - results are not sufficient to support a final conclusion.
   - results are not objectively based on valid experiments.
   - they repeat results already published by the same or other authors before the submission to AR.
   - plagiarism is detected by plagiarism screening services.
   (Rejection rate (2016): 66%).

10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.

11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org

12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.

13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service.

(Copyright© 2020 - International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
**General Policy**

**CANCER GENOMICS & PROTEOMICS** (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal’s scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission.

CGP is published bimonthly by the International Institute of Anticancer Research (IIAR) and is available online only and open access with Stanford University HighWire Press. For more information please visit our website www.cgp.iiarjournals.org.

**Editorial Office:** International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

**U.S. Branch:** Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

**E-mail:** journals@iiar-anticancer.org; IIAR WEBSITES: www.iiar-anticancer.org and www.iiarjournals.org

---

**Selection of Recent Articles**


Pazopanib Inhibits Tumor Growth, Lymph-node Metastasis and Lymphangiogenesis of an Orthotopic Mouse of Colorectal Cancer. G. ZHU, M. ZHAO, Q. HAN, Y. TAN, Y. SUN, M. BOUVET, S.R. SINGH, J. YE, R.M. HOFFMAN (San Diego, CA; Frederick, MD, USA; Fuzhou, PR China)


Chromosome Translocation t(14:21)(q11;q22) Activates Both OLG1 and OLG2 in Pediatric T-cell Lymphoblastic Malignancies and May Signify Adverse Prognosis. I. PANAGOPoulos, L. GORUNOVA, I.M. RINVOLL JOHANSDOTTIR, K. ANDERSEN, A. HOLTH, K. BEISKE, S. HEIM (Oslo, Norway)


Significant Association Between the MiR146a Genotypes and Susceptibility to Childhood Acute Lymphoblastic Leukemia in Taiwan. J.-S. PEI, W.-S. CHANG, P.-C. HSU, C.-C. CHEN, Y.-T. CHIN, T.-L. HUANG, Y.-N. HSU, C.-C. KUO, Y.-C. WANG, C.-W. TSAI, C.-L. GONG, D.-T. BAU (Taoyuan; Taichung, Taiwan, ROC)


MicroRNAs Involved in Metastasis of Hepatocellular Carcinoma: Target Candidates, Functionality and Efficacy in Animal Models and Prognostic Relevance. U.H. WEIDLE, D. SCHMID, F. BIRZELLE, U. BRINKMANN (Fenningen, Germany; Basel, Switzerland)

Increased Expression of Gremlin1 Promotes Proliferation and Epithelial Mesenchymal Transition in Gastric Cancer Cells and Correlates With Poor Prognosis of Patients With Gastric Cancer. Z. SUN, S. CAI, C. LIU, Y. CUI, J. JI, W.G. JIANG, L. YE (Cardiff, UK; Beijing, PR China)

Comparison of Macrophage Activation Using γ-Globulin and Serum-derived Macrophage Activating Factor. M. AKAMATSU, R. MASHIBA, K. KAWAKATSU, M. ISHIKAWA, T. NISHIKATA (Kobe, Japan) .......... 4707

Attempt to Construct an In Vitro Model of Enhancement of Macrophage Phagocytosis Via Continuous Administration of LPS. K. YAMAMOTO, H. MIZOBUCHI, M. YAMASHITA, H. INAGAWA, C. KOHCHI, G.-I. SOMA (Kagawa; Niigata, Japan) ...................................................... 4711

Mastication Affects Transcriptomes of Mouse Microglia. M. SEKI, A. HAINO, T. ISHIKAWA, H. INAGAWA, G.-I. SOMA, H. TERADA, M. NASHIMOTO (Niigata; Kagawa, Japan) ............................................. 4719

Clinical Studies


Useful Cases of Patients With Developmental Disorders Improved by Oral Administration of LPS Derived from Pantoea agglomerans. A. MORISHIMA, R. ZHANG, T. NAGAO, H. INAGAWA (Osaka; Takamatsu; Niigata, Japan) .................................................................................................................. 4755


Salvage Surgery for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Downstaged by Hepatic Arterial Infusion Chemotherapy. Y. GOTO, T. HISAKA, H. SAKAI, K. TAKAGI, S. FUKUTOMI, Y. AKAGI, K. OKUDA (Kurume, Japan) .................................................................................................................. 4773

Pilot Study of Irinotecan and S-1 (IRIS) for Advanced and Metastatic Breast Cancer. T. TANAKA, M. TANAKA, H. FURUSAWA, Y. KAMADA, Y. SAGARA, K. ANAN, K. MIYAMA, Y. KAI, T. UGA, K. TAMURA, S. MITSUYAMA (Fukuoka; Miyazaki; Okinawa; Kagoshima; Oita; Nagasaki, Japan) ..................... 4779

The Impact of Histological Variant on Oncological Outcomes in Patients With Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy. K. TAKEMOTO, J. TEISHIMA, Y. KOHADA, K. IKEDA, H. NAGAMATSU, A. GORIKI, S. INOUE, T. HAYASHI, M. KAIJWARA, A. MATSUBARA (Hiroshima; Oita, Japan) ...................................................... 4787

Artificial Intelligence in Ovarian Cancer Diagnosis. M. AKAZAWA, K. HASHIMOTO (Tokyo, Japan) .... 4795

Clinical Outcomes of Surgical Resection for Brain Metastases from Non-small Cell Lung Cancer. T. NAKAO, T. OKUDA, H. YOSHIOKA, M. FUJITA (Osaka, Japan) .................................................................................................................. 4801

Errata ........................................................................................................................................................................ 4805

Contents continued
Cetyltrimethylammonium Bromide Disrupts the Mesenchymal Characteristics of HA22T/VGH Cells Via Inactivation of c-Met/PI3K/Akt/mTOR Pathway. C.-H. YUE, C.-H. CHEN, W.-T. LEE, T.-F. SU, Y.-R. PAN, Y.-P. CHEN, F.-M. HUANG, C.-J. LEE (Taichung; Miaoli; Changhua, Taiwan, ROC) .......................................................... 4513


Ginseng Seed Oil Inhibits the Growth of Estrogen Receptor-positive Breast Cancer Cells. T.H. KIM, S.-C. KWON, J.N. KIM, J.-H. YOON, S.-G. CHO (Chungbuk; Pusan, Republic of Korea) .................................................. 4529

The Roles of Connexin 26, 32, and 43 as Prognostic Factors for Gastric Cancer. E.Y. KIM, K.H. JUN, K. YIM (Seoul, Republic of Korea) ............................................................................................................................ 4537

Exploring Flavonoids for Potential Inhibitors of a Cancer Signaling Protein PI3Kγ Kinase Using Computational Methods. M. REHAN, M.M. MAHMOUD, S. TABREZ, H.M.A. HASSAN, G.M. ASHRAF (Jeddah, Kingdom of Saudi Arabia; Cairo, Egypt) ........................................................................................................ 4547

Overexpression of Holocarboxylase Synthetase Predicts Lymph Node Metastasis and Unfavorable Prognosis in Breast Cancer. W. SUKJOI, S. SIRITUTSOONTORN, P. CHANSONGKROW, S. WAIWITLIKIT, S.W. POLYAK, M. WARNNISSORN, V. CHAROENSAWAN, C. THUWAJIT, S. JITRAPAKDEE (Bangkok; Nakhon Pathom, Thailand; Brighton, UK; Adelaide, Australia).................................................................................................................... 4557


ABSTRACTS OF THE 30th ANNUAL MEETING OF THE ITALIAN SOCIETY OF URO-ONCOLOGY (SIUOrO), 26 - 29 September 2020 (Virtual Meeting) ................................................................................................................................. 4571-4650

PROCEEDINGS OF THE 23RD ANNUAL MEETING OF THE SOCIETY OF BIOTHERAPEUTIC APPROACHES. 7 December, 2019 (Niigata, Japan) .................................................................................................................... 4651-4804

Review

Current Status of Therapeutic Drug Monitoring of 5-Fluorouracil Prodrugs. Y. HASHIMOTO, Y. YOSHIDA, T. YAMADA, N. AISU, G. YOSHIMATSU, F. YOSHIMURA, S. HASEGAWA (Fukuoka, Japan) .................. 4655

Experimental Studies


Effect of Isomerization of TX-2036 Derivatives on the Interaction With Tyrosine Kinase Domain of EGF Receptor. K. OHKURA, A. TABATA, Y. UTO, H. HORI (Suzuka; Tokushima, Japan) ........................................................................................................................ 4675

Enhanced Effect of Hyaluronic and Elastin Synthesis in Fibroblasts Through Lipopolysaccharide-activated Macrophages. T. HONDA, S. TSUTSUI, C. KOHCHE, H. INAGAWA (Kanagawa; Kagawa; Niigata, Japan) ........ 4681

MK615 Suppresses Hypoxia Tolerance by Up-regulation of E-cadherin in Colorectal Cancer Cells With Mutant KRAS. K. NISHI, T. TSUNODA, Y. UCHIDA, T. SUETA, M. SAWATSUBASHI, T. YAMANO, Y. HASHIGUCHI, A. SWAIN, S. SHIRASAWA, T. SAKATA (Fukuoka, Japan) .................. 4687


Contents continued on the preceding page
Risk Factors for Recurrence in Esophageal Squamous Cell Carcinoma Without Pathological Complete Response After Trimodal Therapy. T. KUROKAWA, Y. HAMAI, M. EMI, Y. IBUKI, T. YOSHIKAWA, M. OHSAWA, R. HIROHATA, M. OKADA (Hiroshima, Japan) .............................................................. 4387

Prognostic Stratification of the IMDC Intermediate Risk Group After Treatment With First-line Molecular-targeted Therapy for Metastatic Renal Cell Carcinoma. K. TAKAHARA, R. ANDO, K. KANAO, T. ITO, H. MIYAKE, M. SUMITOMO, T. YASUI, R. SHIROKI (Toyoake; Nagoya; Hida ka; Hamamatsu, Japan) .......... 4395

EGFR Mutated Lung Adenocarcinoma Metastasis to the Pancreas Mimicking Primary Pancreatic Ductal Carcinoma. C. CAO, M.X. KONG, M. KAPALI, K. MOEZARDALAN, Q. SHI, A. AZARM, J. LAI (Sacramento, CA; Providence, RI; Atlanta, GA, USA) .............................................................................................. 4401

Predictive Factors for Non-sentinel Nodal Metastasis in Patients With Sentinel Lymph Node-positive Breast Cancer. Y. ISHIZUKA, Y. HORIMOTO, M. NAKAMURA, A. ARAKAWA, T. FUJITA, K. IIJIMA, M. SAI TO (Tokyo; Urayasu, Japan) ........................................................................................................................................... 4405


Fibrosis or Necrosis in Resected Lymph Node Indicate Metastasis Before Chemoradiotherapy in Lung Cancer Patients. Y. TAKAHASHI, J. SOH, K. SHIEN, H. YAMAMOTO, M. YAMANE, K. KIURA, S. KANAZAWA, H. YANAI, S. TOYOOKA (Okayama, Japan) ................. 4419

Experimental Studies

Mosaic Recombinant Adeno-associated Virus Vector rAAV/DJ/CAG for Targeted Gene Delivery to Melanoma Cells Metastasized to the Lung. M. CZAJKA, A. ZAJKOWSKA, M. GAWLAK, M. BUJALSKA-ZADROZNY, M. MALECKI (Warsaw, Poland) .............................................................................................................. 4425


A Novel Anti-inflammatory Phenotype Transformed by Repetitive Low-dose Lipopolysaccharide in Primary Peritoneal Tissue-resident Macrophages. H. MIZOBUCHI, K. YAMAMOTO, M. YAMASHITA, H. INAGAWA, C. KO HCHI, G.-I. SOMA (Kagawa; Niigata, Japan) .............................................................................................................. 4457

MiR-196a-2 Genotypes Determine the Susceptibility and Early Onset of Childhood Acute Lymphoblastic Leukemia. C.-C. CHEN, P.-C. HSU, L.-C. SHIH, Y.-N. HSU, C.-C. KUO, C.-Y. CHAO, W.-S. CHANG, C.-W. TSAI, D.-T. BAU, J.-S. PEI (Taoyuan; Taichung, Taiwan, ROC) .............................................................. 4465

Novel Anti-CD70 Antibody Drug Conjugate for the Treatment of Adult T-Cell Leukemia (ATL). R. YOKOTA, S. HASHIMOTO, I. WATANABE, S. KISHIMOTO, M. TOYAMA, M. OKAMOTO, M. YOSHIMITSU, K. ISHITSUKA, Y. ITO, M. BABA (Kagoshima, Japan) ........................................................................ 4471

Clinical Implications of Cancer Stem Cell Markers and ABC Transporters as a Predictor of Prognosis in Colorectal Cancer Patients. B.-H. KIM, H.-K. OH, D.-W. KIM, S.-B. KANG, Y. CHOI, E. SHIN (Seoul; Seongnam; Hwaseong, Republic of Korea) ......................................................... 4481


Involvement of Corticotropin-releasing Hormone-related Peptides in Cellular Stress Caused by Anticancer Drugs in Colorectal Cancer. G. KUWATA, K. IKEDA, Y. MANOME (Tokyo, Japan) .......................................................... 4505

Contents continued on the preceding page
Interest for a Systematic Rehabilitation Program Including Physical Exercise and Lifestyle Accompaniment for Women Recently Treated for Early Breast Cancer: A Comparative Study. S. MARECHAL, M.-P. GRAAS, L. COLLARD, M. COLLIN, V. RASKIN, G. BRANDS, P. EVRARD, J.-P. LOBELLE, C. FOCAN (Liège; Beernem, Belgium)................................. 4253

Association of C677T and A1298C MTHFR Polymorphisms and Fluoropyrimidine-induced Toxicity in Mestizo Patients With Metastatic Colorectal Cancer. A. RAMOS-ESQUIVEL, R. CHINCHILLA, M. VALLE (Barcelona, Spain; San Jose, Costa Rica) ............................................................................................................ 4263

Skeletal Muscle Mass Depletion After Gastrectomy Negatively Affects the Prognosis of Patients With Gastric Cancer. Y. KANAZAWA, T. YAMADA, D. KAKINUMA, K. MATSUNO, F. ANDO, I. FUJITA, H. KANNO, S. KATO, H. YOSHIDA (Tokyo, Japan) ........................................................................................................................................................................ 4271

Interstitial Brachytherapy for Limited (<4 cm) and Large (≥4 cm) Hepatic Metastases from Rare and Less Common Cancers. C. HEINZE, J. OMARI, R. DAMM, P. HASS, T. BRUNNER, A. SUROV, R. SEIDESTICKER, M. SEIDENSTICKER, J. RICKE, M. POWERSKI, M. PECH (Magdeburg; Munich, Germany) ........................................... 4281

Comparison of Tolerability Between 2-Weekly and 3-Weekly Docetaxel Regimen in Castration-resistant Prostate Cancer. Y. SHIMURA, Y. SUGA, S. ITAI, H. IWAMOTO, Y. TAKEZAWA, H. YAEGASHI, K. IZUMI, T. SHIMADA, Y. SAJ, R. MATSUSHITA, A. MIZOKAMI (Kanazawa, Japan) .......................................................... 4291

Increase in Circulating Tumor Cells in Invasive Bladder Cancer After Transurethral Resection of Bladder Tumor. N. HAGA, K. TSUBOUCHI, H. MARUTA, T. KOGUCHI, S. HOSHI, S. OGAWA, H. AKAIHATA, J. HATA, Y. KOJIMA (Fukushima; Fukuoka, Japan) .............................................................................................................. 4299

Ephrin Receptor B2 Expression May Be a Prognostic Marker for Patients With Cancer: A Meta-analysis. H.M. KOH, C.L. HYUN, B.G. JANG, H.J. LEE (Changwon; Jeju; Cheonan, Republic of Korea) ..................... 4309


Correlation of Pathological Complete Response With Tumor Volume Reduction During Neoadjuvant Chemoradiotherapy in Lung Cancer. S. TAKAHASHI, T. GO, M. ANADA, T. KINOSHITA, T. NISHIDE, H. YOKOMISE, T. SHIBATA (Kagawa, Japan) ................................................................. 4327

Practice Variation in the Adjuvant Treatment of Colon Cancer in the Netherlands: A Population-based Study. L. KEIKES, M. KOOPMAN, V.E.P.P. LEMMENS, M.G.H. VAN OIJEN, C.J.A. PUNT (Amsterdam; Utrecht; Rotterdam, the Netherlands) ....................................................................................................................... 4331

Predictors of Postoperative Ascites After Hepatic Resection in Patients With Hepatocellular Carcinoma. N. HARIMOTO, K. ARAKI, N. ISHII, R. MURANUSHI, K. HOSHINO, K. HAGIWARA, M. TSUKAGOSHI, T. IGARASHI, A. WATANABE, N. KUBO, K. SHIRABE (Maebashi, Japan) ...................................................................................................................... 4343

Diagnostic Role of Contrast-enhanced Ultrasound in the Discrimination of Malignant Portal Vein Thrombosis in Patients With Hepatocellular Carcinoma. J.H. KWON, S.H. YOO, S.W. NAM, Y.J. LEE, Y.R. SHIN (Incheon; Daejeon; Seoul, Republic of Korea) ................................................................................................................................. 4351

Better Cancer-specific Survival in Younger Patients With Stage III Colorectal Cancer: A Propensity Score Matching Study From Japan. L. WANG, Y. HIRANO, G. HENG, T. ISHII, H. KONDO, K. HARA, N. OBARA, M. ASARI, S. YAMAGUCHI (Saitama, Japan) ......................................................................................................................... 4365

Giant Cell Tumor of Tendon Sheath With a t(1;1)(p13;p34) Chromosomal Translocation. S. NAKAYAMA, J. NISHIO, K. NAKATANI, K. NABESHIMA, T. YAMAMOTO (Fukuoka, Japan) ............................................................................................................................. 4373

A Model for Predicting DNA Mismatch Repair-deficient Colorectal Cancer. K. CHIKATANI, N. CHIKA, O. SUZUKI, T. SAKIMOTO, K. ISHIBASHI, H. EGUCHI, Y. OKAZAKI, H. ISHIDA (Saitama; Tokyo, Japan) ...................... 4379

Contents continued on the preceding page